[Clinical studies of SM-4300 in children].
In vitro experiment with phagocytic and bactericidal activity of human neutrophils, SM-4300 augmented opsonic activity against Pseudomonas aeruginosa. After a single dose of 200 mg/kg body weight SM-4300 to a child with common variable immunodeficiency (CVI), serum IgG concentration/time curve was similar to that after PEG-Ig administration. In combination therapies with SM-4300 and antibiotics in 8 children with bacterial infections, beneficial efficacy of SM-4300 was observed. There was no adverse reaction in 16 times injections to 9 children with bacterial infections and 5 times to a child with CVI.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000188:drug therapy*; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage / Q000378:metabolism; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D007223:Infant; D007700:Kinetics; D008297:Male; D010587:Phagocytosis; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; C044640:SM-4300